Early diagnosis is essential for a good prognosis of patients with endometrial cancer; however, there are currently no noninvasive tests available.
Despite the good prognosis with early diagnosis, a significant minority of women will recur, and biomarkers are needed to stratify patients according to their risk of recurrence.
